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Abstract
The Consolidated Standards of Reporting Trials (CONSORT) statement is a guideline designed to improve the
transparency and quality of the reporting of randomised controlled trials (RCTs). In this article we present an
extension to that statement for randomised pilot and feasibility trials conducted in advance of a future definitive
RCT. The checklist applies to any randomised study in which a future definitive RCT, or part of it, is conducted on a
smaller scale, regardless of its design (eg, cluster, factorial, crossover) or the terms used by authors to describe the
study (eg, pilot, feasibility, trial, study). The extension does not directly apply to internal pilot studies built into the
design of a main trial, non-randomised pilot and feasibility studies, or phase II studies, but these studies all have
some similarities to randomised pilot and feasibility studies and so many of the principles might also apply.
The development of the extension was motivated by the growing number of studies described as feasibility or
pilot studies and by research that has identified weaknesses in their reporting and conduct. We followed
recommended good practice to develop the extension, including carrying out a Delphi survey, holding a consensus
meeting and research team meetings, and piloting the checklist.
The aims and objectives of pilot and feasibility randomised studies differ from those of other randomised trials.
Consequently, although much of the information to be reported in these trials is similar to those in randomised
controlled trials (RCTs) assessing effectiveness and efficacy, there are some key differences in the type of information
and in the appropriate interpretation of standard CONSORT reporting items. We have retained some of the original
CONSORT statement items, but most have been adapted, some removed, and new items added. The new items cover
how participants were identified and consent obtained; if applicable, the prespecified criteria used to judge whether or
how to proceed with a future definitive RCT; if relevant, other important unintended consequences; implications for
progression from pilot to future definitive RCT, including any proposed amendments; and ethical approval or approval
by a research review committee confirmed with a reference number.
This article includes the 26 item checklist, a separate checklist for the abstract, a template for a CONSORT flowchart for
these studies, and an explanation of the changes made and supporting examples. We believe that routine use of this
proposed extension to the CONSORT statement will result in improvements in the reporting of pilot trials.
Editor’s note: In order to encourage its wide dissemination this article is freely accessible on the BMJ and Pilot and
Feasibility Studies journal websites.
The Consolidated Standards of Reporting Trials (CON-
SORT) statement (www.consort-statement.org) is a guide-
line designed to improve the transparency and quality of the
reporting of randomised trials. It was first published in 1996,
revised in 2001, last updated in 2010 [1, 2] and published
simultaneously in 10 leading medical journals, including the
Lancet, JAMA, BMJ, Annals of Internal Medicine, and PLoS
Medicine. The CONSORT statement comprises a checklist
of the minimum essential items that should be included in
reports of randomised trials and a diagram documenting the
flow of participants through the trial.
The development of CONSORT guidelines has received
considerable international recognition. The CONSORT
statement has been cited more than 8000 times and has
received support from the World Association of Medical
Editors, Council of Science Editors, International Com-
mittee of Medical Journal Editors, and more than 600
journals worldwide. Several studies have examined the
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impact of the statement on the reporting quality of pub-
lished randomised trials and found that adoption of the
statement leads to an increase in reporting quality [3].
In addition to the CONSORT statement, extensions to
the CONSORT checklist for reporting trials with non-
inferiority, equivalence, and cluster or pragmatic designs
have been published [4–6], as have extension checklists
for reporting harms [7], different types of interventions
(non-drug treatments [8] and herbal interventions [9]),
and patient reported outcomes [10]. The main CONSORT
statement and all of the current extensions focus on trials
for which the research question centres on the effective-
ness or efficacy of an intervention. However, some rando-
mised trials, that we refer to as pilot and feasibility trials,
do not have effectiveness or efficacy as their primary
focus. Rather, they are designed to support the develop-
ment of a future definitive RCT. By “definitive” in this
context we mean an appropriately powered study focusing
on effectiveness or efficacy. The need for high standards
in conduct and reporting applies just as much to pilot and
feasibility trials as it does to definitive trials.
Scope of this paper
In this article we present an extension to the CONSORT
statement for randomised pilot and feasibility trials con-
ducted in advance of a future definitive RCT. In keeping
with the broad scope of CONSORT, the future definitive
RCT might evaluate either the efficacy or the effectiveness
of an intervention. The primary aim of the randomised
pilot or feasibility trial, however, is to assess feasibility of
conducting the future definitive RCT.
We make no distinction in this extension between
pilot and feasibility randomised trials. Although in prac-
tice we recognise that different researchers might have
preferences for different terms, the lack of distinction is
based on a framework developed by the authors, which
defines such studies [11]. In that framework, a feasibility
study for a future definitive RCT asks whether the future
trial can be done, should be done, and, if so, how. Pilot
studies are a subset of feasibility studies. They ask the
same questions about feasibility (whether the future trial
can be done, should be done, and, if so, how) but have a
particular design feature: in a pilot study (that might or
might not be randomised) the future definitive RCT, or
part of it, is conducted on a smaller scale.
For brevity, we use the term “pilot trial” to refer to any
randomised study in which a future definitive RCT, or a
part of it, is conducted on a smaller scale. However,
these studies might legitimately be referred to using any
of the following terms: pilot RCT, randomised pilot trial,
pilot trial, pilot study, randomised pilot study, feasibility
RCT, randomised feasibility trial, feasibility trial, feasibility
study, or randomised feasibility study. In fact, we have set
no restrictions on the terminology used to describe pilot
trials; rather we have specified only that they are rando-
mised, conducted in advance of a future definitive RCT,
and primarily aim to assess feasibility.
The development of this extension was motivated by
the growing number of studies described as feasibility or
pilot studies [12] and by research that has identified
weaknesses in the reporting and conduct of these studies
[12–15]. We expect that improved reporting quality will
lead to more high quality examples of pilot trials, enab-
ling yet further improvements in the conduct of pilot tri-
als and making it possible for readers to use the results
of reported pilot studies in preparing future trials in
similar settings and with similar participants. Because the
purpose of a pilot trial (to assess feasibility) is different
from that of the future definitive RCT (to assess effective-
ness or efficacy), the focus of the reporting should be dif-
ferent, and that difference is reflected in the extension.
The extension does not apply to internal pilot studies
that are built into the design of a main trial, or to non-
randomised pilot and feasibility studies. However, much
of what is presented here might apply to, or be adapted
to apply to, these types of pilot or feasibility studies or
similar types of trial, such as “proof of concept” or phase
II trials done in the development of drugs [16, 17]. Proof
of concept or phase II trials are small RCTs the main ob-
jective of which are to inform the sponsor whether or
not to continue the development of a drug with larger
trials. Similar to pilot trials, the focus is on assessing the
feasibility of further development rather than assessing
effectiveness or efficacy. However, to do this these trials
tend to focus on aspects such as safety and potential ef-
fectiveness or efficacy. They might use accepted
methods devised for phase II trials [18] to assess the
outcome to be used in a future phase III trial (which
could be meta-analysed if required) [19] or use surrogate
outcomes—that is, intermediate measures, often biochem-
ical, which have less direct impact on a patient than, for
example, cure or death, but which should be associated
with these “hard” outcomes. Safety, and potential effect-
iveness or efficacy, are usually less important in pilot trials,
where the focus is on the development of interventions
and their evaluation and where issues related to feasibility
might be different. Nevertheless, pilot trials do sometimes
assess potential effectiveness using surrogate outcomes.
For example, oxygenation of the blood as a surrogate
measure for improved lung function and survival [20] or
the number of steps walked each day as a surrogate for
clinical measures of heart disease [21].
Here we present an extension to the standard CONSORT
guidelines for reporting RCTs. Many investigators, however,
use qualitative research alongside other methods to assess
feasibility. The amount of qualitative work conducted at the
pilot and feasibility stage, its relation with any pilot trial,
and the way investigators want to report this work, varies.
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Stand-alone qualitative studies that are reported separately
from the pilot trial, such as Hoddinott et al. and Schoultz et
al. [22, 23] should follow appropriate reporting guidelines
[24–26] and should provide link references to other pilot
work carried out in preparation for the same definitive trial.
When qualitative work is reported within the primary
report of a pilot trial [27], it is not always possible to
put sufficient detail into the methods section of the re-
port to comply with reporting guidelines for qualitative
studies. If this is the case, we recommend an online
supplement or appendix to report the methods in detail.
O’Cathain et al., Hoddinott et al., and Schoultz et al. have
provided guidelines and examples for conducting qualitative
feasibility studies alongside pilot trials [22, 23, 26, 28, 29].
Adapting the CONSORT statement for pilot trials
The development of this CONSORT extension for pilot
trials is described briefly here and in detail elsewhere
[30]. Before developing the checklist for this extension,
the research team agreed on the definitions of pilot and
feasibility studies. This was done by initially considering
pilot and feasibility studies to be discrete types of study
and therefore in need of separate checklists. However,
preliminary work concluded that pilot and feasibility
studies could not be defined in a mutually exclusive way,
compatible with current understanding and the use of
these terms among the research community. We there-
fore adopted an overarching definition of feasibility stud-
ies, with pilot studies being a subset, and developed a
single checklist for such studies that use a randomised
approach, referred to as pilot trials in this paper. The
process of agreeing on the definitions of feasibility and
pilot studies and the underpinning conceptual framework
are reported separately [11]. That work was done in paral-
lel with the development of the checklist (Table 1). We
used the principles in Box 1 to guide the work.
In stage 1, the research team met and worked through
each of the existing CONSORT checklist items, agreeing
whether each was relevant and should be retained, not
relevant and should be excluded, or needed rewording in
the context of either a feasibility study or pilot study.
This resulted in two checklists. We then applied the re-
vised checklists to a sample of 30 articles identified from
previous work [13, 15] and our own personal collections.
In stage 2, we used a modified Delphi survey to seek
consensus on the appropriateness of each of the checklist
items. Participants (n = 93) were asked to rate each item on
a scale of 1 to 9 (1 = not at all appropriate to 9 = completely
appropriate). They were also given the opportunity to com-
ment on each item, definitions of pilot and feasibility stud-
ies, and the perceived usefulness of the checklist [11].
In stage 3, participants in the Delphi survey were asked
to review responses for items that 70 % or more of partici-
pants had rated as 8 or 9 in round 1 of the survey and to
make additional comments on these items. They were
asked to review the remaining items and classify each
using one of four options: discard, keep, unsure, or no
opinion. They were also asked to add any items they
Table 1 Stages of adapting CONSORT statement for pilot trials
Stage Activity Participants Venue (or virtual meeting) Date
1 Drafting of definitions and
preliminary adaptation of
CONSORT checklist items
Research team London Dec 2012
2 1st round of modified
Delphi process using
online administration
Invited experts from
research community
(trialists, methodologists,
statisticians, funders, and
journal editors)
Email distribution Jul-Aug 2013
3 2nd round of modified
Delphi process
As for round 1 Email distribution Sept-Oct 2013
4 Review of results from
Delphi process and
redrafting checklist
Research team London Feb 2014
5 Consensus meeting Invited experts (trialists,
methodologists, statisticians,
funders, journal editors, and
members of CONSORT
executive)
Oxford Oct 2014
6 Review of consensus
meeting feedback and
drafting final checklist
Research team Email consultation with consensus
participants; and meetings in London
Dec 2014-Dec 2015; and
Jan, Jun, Dec 2015
7 Further review and piloting Research team Email consultation with consensus
participants; and piloting by
independent researchers writing
up pilot studies
Mar 2016; and Jan-Mar 2016
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believed had been missed. In total 93/120 (77.5 %) re-
sponses were received for round 1 and 79/93 (84.9 %)
for round 2.
In stage 4, the research team met face to face to review
the feedback from the Delphi survey and to revise the
checklist. In stage 5, the revised checklist was then fur-
ther reviewed in detail during a two day expert consen-
sus meeting. In stage 6, some checklist items were
reworded to ensure clarity of meaning and purpose, and
the research team met face to face a further three times
to agree on the final wording of the checklist, identify
examples of good reporting, and develop the explanation
and elaboration section of this paper. A full draft of the
paper was then sent to members of the consensus meeting
to ensure it fully reflected the discussion of the meeting.
Table 2 presents the final checklist, laid out in accord-
ance with other CONSORT extensions. Items in the
standard checklist column should be adhered to unless
the extension column indicates a change in the item.
Box 1 lists the methodological considerations and princi-
ples that guided the process.
Extension of CONSORT 2010 to pilot trials
Title and abstract
- Item 1a
- Standard CONSORT item: identification as a rando-
mised trial in the title
- Extension for pilot trials: identification as a pilot or
feasibility randomised trial in the title
- Example 1 (using the words pilot, randomised, and trial)
“Bespoke smoking cessation for people with severe
mental ill health (SCIMITAR): a pilot randomised
controlled trial” [31]
- Example 2 (using the words feasibility, randomised,
and trial)
“A cluster randomised feasibility trial evaluating
nutritional interventions in the treatment of
malnutrition in care home adult residents” [32]
- Explanation
The primary focus of these guidelines is randomised
pilot and feasibility trials. To ensure that these types of
studies can be easily identified from specific search criteria,
a title containing the descriptors “pilot” or “feasibility” as
well as “randomised” provides a necessary, recognised ter-
minology for selecting randomised pilot and feasibility tri-
als [13]. This would also enable these studies to be easily
indexed in electronic databases, such as PubMed [33]. Al-
though the descriptors might appear in the title for many
studies, they might not necessarily occur together, as in:
“Feasibility of a randomised trial of a continuing medical
education program in shared decision-making on the use
of antibiotics for acute respiratory infections in primary
care: the DECISION+ pilot trial [34].” Furthermore, in
some cases authors might use the phrase “randomised pilot
study” or “randomised feasibility study,” as in “‘Not just an-
other walking program’: Everyday Activity Supports You
(EASY) model—a randomized pilot study for a parallel
randomized controlled trial [21].” Such papers could be
identified in appropriate searches. However, in general we
recommend the descriptors are given together in one
phrase, and the word “trial” rather than “study” is used, as
in “randomised pilot trial” or “randomised feasibility trial.”
- Item 1b
- Standard CONSORT item: structured summary of
trial design, methods, results, and conclusions (for specific
guidance see CONSORT for abstracts) [35, 36].
- Extension for pilot trials: structured summary of pilot
trial design, methods, results, and conclusions (for spe-
cific guidance see CONSORT abstract extension for
pilot trials) (Table 3)
- Example
See Figs. 1, 2 and 3 [21].
Box 1. Methodological considerations and principles
that guided the development of the CONSORT extension
to pilot trials
• The rationale of a pilot trial is to investigate areas of
uncertainty about the future definitive RCT
• The primary aims and objectives of a pilot trial are therefore
about feasibility, and this should guide the methodology used
in the pilot trial
• Assessments or measurements to address each pilot trial
objective should be the focus of data collection and analysis.
This might include outcome measures likely to be used in the
definitive trial but, equally, it might not
• Since the aim of a pilot trial is to assess the feasibility of
proceeding to the future definitive RCT, a decision process about
how to proceed needs to be built into the design of the pilot trial.
This might involve formal progression criteria to decide whether to
proceed, to proceed with amendments, or not to proceed
• Methods used to address each pilot trial objective can be
qualitative or quantitative. A mixed methods approach could result
in both types of data being reported within the same paper.
Equally, a process evaluation or other qualitative study can be
done alongside a pilot trial and reported separately in more detail
• The number of participants in a pilot study should be based on
the feasibility objectives and some rationale should be given
• Formal hypothesis testing for effectiveness (or efficacy) is not
recommended. The aim of a pilot trial is not to assess effectiveness
(or efficacy) and it will usually be underpowered to do this
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Table 2 CONSORT checklist of information to include when reporting a pilot trial
Section/topic
and item No
Standard checklist item Extension for pilot trials Page No where
item is reported
Title and abstract
1a Identification as a randomised trial in the title Identification as a pilot or feasibility randomised
trial in the title
1b Structured summary of trial design, methods, results,
and conclusions (for specific guidance see CONSORT
for abstracts)
Structured summary of pilot trial design, methods,
results, and conclusions (for specific guidance see
CONSORT abstract extension for pilot trials)
Introduction
Background and objectives:
2a Scientific background and explanation of rationale Scientific background and explanation of rationale
for future definitive trial, and reasons for
randomised pilot trial
2b Specific objectives or hypotheses Specific objectives or research questions for pilot
trial
Methods
Trial design:
3a Description of trial design (such as parallel, factorial)
including allocation ratio
Description of pilot trial design (such as parallel,
factorial) including allocation ratio
3b Important changes to methods after trial commencement
(such as eligibility criteria), with reasons
Important changes to methods after pilot trial
commencement (such as eligibility criteria),
with reasons
Participants:
4a Eligibility criteria for participants
4b Settings and locations where the data were collected
4c How participants were identified and consented
Interventions:
5 The interventions for each group with sufficient details to
allow replication, including how and when they were
actually administered
Outcomes:
6a Completely defined prespecified primary and secondary
outcome measures, including how and when they were
assessed
Completely defined prespecified assessments
or measurements to address each pilot trial
objective specified in 2b, including how and
when they were assessed
6b Any changes to trial outcomes after the trial commenced,
with reasons
Any changes to pilot trial assessments or
measurements after the pilot trial commenced,
with reasons
6c If applicable, prespecified criteria used to judge
whether, or how, to proceed with future
definitive trial
Sample size:
7a How sample size was determined Rationale for numbers in the pilot trial
7b When applicable, explanation of any interim analyses and
stopping guidelines
Randomisation:
Sequence generation:
8a Method used to generate the random allocation sequence
8b Type of randomisation; details of any restriction (such as
blocking and block size)
Type of randomisation(s); details of any
restriction (such as blocking and block size)
Allocation concealment mechanism:
9 Mechanism used to implement the random allocation
sequence (such as sequentially numbered containers),
describing any steps taken to conceal the sequence
until interventions were assigned
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Table 2 CONSORT checklist of information to include when reporting a pilot trial (Continued)
Implementation:
10 Who generated the random allocation sequence, enrolled
participants, and assigned participants to interventions
Blinding:
11a If done, who was blinded after assignment to interventions
(eg, participants, care providers, those assessing outcomes)
and how
11b If relevant, description of the similarity of interventions
Analytical methods:
12a Statistical methods used to compare groups for primary
and secondary outcomes
Methods used to address each pilot trial objective
whether qualitative or quantitative
12b Methods for additional analyses, such as subgroup analyses
and adjusted analyses
Not applicable
Results
Participant flow (a diagram is strongly recommended):
13a For each group, the numbers of participants who were
randomly assigned, received intended treatment, and were
analysed for the primary outcome
For each group, the numbers of participants who
were approached and/or assessed for eligibility,
randomly assigned, received intended treatment,
and were assessed for each objective
13b For each group, losses and exclusions after randomisation,
together with reasons
Recruitment:
14a Dates defining the periods of recruitment and follow-up
14b Why the trial ended or was stopped Why the pilot trial ended or was stopped
Baseline data:
15 A table showing baseline demographic and clinical
characteristics for each group
Numbers analysed:
16 For each group, number of participants (denominator)
included in each analysis and whether the analysis was by
original assigned groups
For each objective, number of participants
(denominator) included in each analysis. If
relevant, these numbers should be by randomised
group
Outcomes and estimation:
17a For each primary and secondary outcome, results for each
group, and the estimated effect size and its precision (such
as 95 % confidence interval)
For each objective, results including expressions
of uncertainty (such as 95 % confidence interval)
for any estimates. If relevant, these results should
be by randomised group
17b For binary outcomes, presentation of both absolute and
relative effect sizes is recommended
Not applicable
Ancillary analyses:
18 Results of any other analyses performed, including subgroup
analyses and adjusted analyses, distinguishing prespecified
from exploratory
Results of any other analyses performed that
could be used to inform the future definitive trial
Harms:
19 All important harms or unintended effects in each group
(for specific guidance see CONSORT for harms)
19a If relevant, other important unintended
consequences
Discussion
Limitations:
20 Trial limitations, addressing sources of potential bias,
imprecision, and, if relevant, multiplicity of analyses
Pilot trial limitations, addressing sources of
potential bias and remaining uncertainty
about feasibility
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- Explanation
Abstracts can follow different structures dependent on
a journal’s style. They are typically around 300 words.
We outline what information should be reported in the
abstract irrespective of style. This information may also
be used for writing conference abstracts. The structure
of the abstract does not differ in format from item 1b of
the standard CONSORT 2010 guidelines. However, its
content focuses on the aims and objectives of the pilot
trial and not on the future definitive RCT.
It is important that the abstract contains pertinent in-
formation on the background, methods, results, and
conclusions in relation to the feasibility objectives and
outcomes, and that it states the study is a “randomised”
pilot trial. This will aid researchers in understanding the
nature of the paper and facilitates electronic searching
through the inclusion of specific key words. A statement
in the abstract that this study is in preparation for a future
definitive RCT is recommended to place it in context. A
description of the areas of uncertainty to be addressed and
a statement of the feasibility aims and objectives should
be included in the background, how these objectives have
been addressed in the methods, and results for each ob-
jective in the results. If there are a limited number of pilot
trial objectives then all should be listed and results for
each reported. If there are many pilot trial objectives, then
agreement should be reached a priori about which are the
most important, to decide whether to proceed to a future
definitive RCT, and only these objectives should be
reported. An explicit statement relating to whether the fu-
ture definitive RCT is likely to go ahead on the basis of
the results of the pilot trial should also form part of the
discussion and conclusions.
Introduction
- Item 2a
- Standard CONSORT item: scientific background and
explanation of rationale
- Extension for pilot trials: scientific background and
explanation of rationale for future definitive trial, and
reasons for randomised pilot trial
- Example
“Reduced fetal movements (RFM) is a frequently seen
problem in maternity care with 6–15 % of women
reporting attending at least one occasion of RFM to
health professionals in the third trimester of
pregnancy. RFM, defined by maternal perception of
significantly reduced or absent fetal activity, is
associated with increased risk of stillbirth and fetal
growth restriction (FGR) due to placental dysfunction.
Despite this association there is a paucity of evidence
to direct clinical management of women presenting
with RFM. This has been recently highlighted by
guidelines from the Royal College of Obstetrics and
Gynaecology (RCOG) and a meta-analysis…The absence
of high-quality evidence has led to wide variation in
management strategies for RFM in high-income
Table 2 CONSORT checklist of information to include when reporting a pilot trial (Continued)
Generalisability:
21 Generalisability (external validity, applicability) of the trial
findings
Generalisability (applicability) of pilot trial
methods and findings to future definitive
trial and other studies
Interpretation:
22 Interpretation consistent with results, balancing benefits
and harms, and considering other relevant evidence
Interpretation consistent with pilot trial
objectives and findings, balancing potential
benefits and harms, and considering other
relevant evidence
22a Implications for progression from pilot to
future definitive trial, including any proposed
amendments
Other information
Registration:
23 Registration number and name of trial registry Registration number for pilot trial and name
of trial registry
Protocol:
24 Where the full trial protocol can be accessed, if available Where the pilot trial protocol can be accessed,
if available
Funding:
25 Sources of funding and other support (such as supply
of drugs), role of funders
26 Ethical approval or approval by research review
committee, confirmed with reference number
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settings…Although there are randomised controlled
trials (RCT) of counting fetal movements by a formal
structure (e.g. count to ten) there have been no
published RCTs of patient management following
presentation with RFM. To undertake an RCT of
patient management raises important practical
concerns including: maternal anxiety for fetal wellbeing,
the need to make a decision regarding participation in a
short period of time due to the acute nature of RFM
and adherence to protocol. Thus, studies have adopted
an approach of changing practice at the unit level in
quality-improvement projects or stepwise cluster RCT
(AFFIRM, NCT01777022). We performed this study to
address whether an RCT of the management of RFM
in individual patients was an appropriate trial design,
and was feasible with regard to i) maternal recruitment
and retention ii) patient acceptability, iii) adherence
to protocol. In addition, we wished to confirm the
prevalence of poor perinatal outcomes in the study
population [37].”
- Explanation
It is important that the scientific background sets the
scene and gives the rationale and justification for the
future definitive RCT and why the pilot trial is needed,
because under the principles of the Helsinki declaration
it is unethical to expose people unnecessarily to the
risks of research [38]. The background and rationale
are nicely illustrated in the example. Other related pub-
lications, or preliminary work such as systematic re-
views, qualitative studies, or additional feasibility work,
or absence of such work because no one has looked at
this topic before, should also be mentioned. The ration-
ale for the randomised pilot trial should be clearly out-
lined, including the areas of uncertainty that need to be
addressed before the future definitive RCT can take
place and why such a trial is needed before proceeding
to the future definitive RCT. This rationale is usually
reported in the final paragraph of the introduction or
background section to provide a justification for the
pilot trial.
Table 3 Extension of CONSORT for abstracts for reporting pilot trials
Item Standard checklist item Extension for pilot trials
Title Identification of study as randomised Identification of study as randomised pilot or feasibility trial
Trial design Description of the trial design (eg, parallel, cluster,
non-inferiority)
Description of pilot trial design (eg, parallel, cluster)
Methods:
Participants Eligibility criteria for participants and the settings
where the data were collected
Eligibility criteria for participants and the settings where the
pilot trial was conducted
Interventions Interventions intended for each group
Objective Specific objective or hypothesis Specific objectives of the pilot trial
Outcome Clearly defined primary outcome for this report Prespecified assessment or measurement to address the
pilot trial objectives*
Randomisation How participants were allocated to interventions
Blinding (masking) Whether or not participants, caregivers, and those
assessing the outcomes were blinded to group
assignment
Results:
Numbers randomised Number of participants randomised to each group Number of participants screened and randomised to each
group for the pilot trial objectives*
Recruitment Trial status†
Numbers analysed Number of participants analysed in each group Number of participants analysed in each group for the pilot
objectives*
Outcome For the primary outcome, a result for each group
and the estimated effect size and its precision
Results for the pilot objectives, including any expressions of
uncertainty*
Harms Important adverse events or side effects
Conclusions General interpretation of the results General interpretation of the results of pilot trial and their
implications for the future definitive trial
Trial registration Registration number and name of trial register Registration number for pilot trial and name of trial register
Funding Source of funding Source of funding for pilot trial
*Space permitting, list all pilot trial objectives and give the results for each. Otherwise, report those that are a priori agreed as the most important to the decision
to proceed with the future definitive RCT
†For conference abstracts
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- Item 2b
- Standard CONSORT item: specific objectives or
hypotheses
- Extension for pilot trials: specific objectives or re-
search questions for pilot trial
- Example 1 (listing objectives as primary and
secondary)
“In this feasibility trial, the research aim was to
explore trial design, staff and resident acceptability of
the interventions and outcome measures and to
provide data to estimate the parameters required to
design a definitive RCT…The primary objectives of
the trial were as follows:
1. To assess how many care homes accepted the
invitation to participate in research.
2. To determine whether the eligibility criteria for
care home residents were too open or too
restrictive by estimating feasible eligibility and
recruitment rate.
3. To assess retention of care homes and residents by
estimating 3 and 6-month follow-up rates.
4. To investigate the acceptability of nutritional support
interventions to malnourished care home residents in
terms of compliance and to care home staff in terms
of adherence to the intervention schedule.
5. To assess the acceptability and feasibility (and factors
influencing this) of the outcome measures as methods
to measure efficacy of the interventions within a
definitive trial.
The secondary objectives of the trial were as follows:
1. To investigate the completion of screening tools and
questionnaires by care home staff.
2. To determine how many malnourished residents
were able to participate in PROMs and to complete
the questionnaires.
3. To pilot a Healthcare resource usage (HCRU)
questionnaire.
4. To measure key outcome domains (for completion
rates, missing data, estimates, variances and 95 %
confidence intervals for the difference between the
intervention arms) for malnourished care home residents,
including physical outcome measures and PROMs.
5. To collect and synthesise data, from which the
Intracluster Correlation Coefficient (ICC) and
sample size of a definitive cluster RCT (CRCT)
could be estimated [32].”
Fig 1 Example of abstract for report of pilot trial [21], shown alongside CONSORT for abstracts extension for pilot randomised trials
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- Example 2 (objectives leading to a mixed methods
study)
“The main aim of the study is to assess the feasibility
of conducting a definitive trial in terms of
recruitment, use and acceptability of the intervention,
follow-up at 3 and 6 months, and data collection
methods. In addition, the study aims to establish
suitable procedures for delivering the intervention
and conducting assessments and procedures for
Fig 3 Track changes version of example abstract for report of pilot trial [21], showing changes between Figs. 1 and 2
Fig 2 Revised version of example abstract for report of pilot trial [21], shown alongside CONSORT for abstracts extension for pilot randomised trials
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ensuring recruitment and retention in the study. Finally,
the study aims to discover whether using a structured,
individualized approach to lifestyle assessment and
referral will improve uptake and participation in
lifestyle- and behaviour-change interventions.
The study will also examine, qualitatively, the
acceptability of the assessment tool to patients in an
acute cardiology setting as well as patients’
experiences of making lifestyle changes in order to
develop effective recruitment and retention strategies.
The study will have a number of quantitative objectives:
1. To determine how many patients accept referral to a
formal lifestyle programme;
2. To determine how many patients participate in a
lifestyle-change intervention or initiate self-managed
change;
3. To investigate the uptake of lifestyle intervention in
relation to subsequent behaviour change and impact
on health-related quality of life, mood and social
satisfaction;
4. To estimate feasible eligibility, recruitment and
refusal rates, and 3- and 6-months follow-up rates;
5. To measure key outcome domains (that is, for
completion rates, missing data, estimates, variances
and 95 % confidence intervals for the difference
between the control and intervention groups) for
patients including clinical indicators and patient-
reported measures of social satisfaction; health-
related quality of life; and mood;
6. To synthesize data to inform the sample size of a
definitive trial;
7. To determine the acceptability (and factors
influencing this) of financial incentives as a method
to encourage behaviour change, their pricing and
factors influencing this [39].”
- Explanation
Although many aspects of feasibility may be related to
each other, an articulation of specific objectives enables
readers to understand the main areas of uncertainty to
be addressed in the pilot trial and provides a working
structure for presenting the methods and results in rela-
tion to these objectives. In addition, a comprehensive list
of objectives enables other researchers to learn from and
adopt similar approaches in their own studies.
It might be beneficial to separate the objectives into
primary objectives (often those on which decisions about
progressing to a future definitive RCT may be made) and
secondary objectives, as in example 1, where feasibility
objectives are primary and questions related to patient
centred outcomes are treated as secondary. Because it
is not always necessary to collect data on patient
centred outcomes, it is important to give the rationale
for collecting such data. For example, the purpose may be
to ensure that certain data can be collected, including
from specific patient groups (eg, elderly people, as in ex-
ample 1), or to ensure that difficult-to-measure concepts
such as lifestyle behaviour change can be assessed appro-
priately in the future definitive RCT (example 2). It might
also be informative to state explicitly which objectives will
be answered using quantitative methods and which using
qualitative methods, as in example 2.
In example 2 the list of quantitative objectives are
quite informative, but they are taken from the published
study protocol. In the published pilot trial the objectives
contained far less detail: “The Healthy Hospital Trial is a
single-center, randomized controlled, 2-arm, parallel-group,
unblinded feasibility trial that was conducted on 2 cardi-
ology wards at the Leeds Teaching Hospitals Trust. Its pri-
mary aim was to explore the feasibility of individualized
lifestyle referral assessment, estimate the rate of recruit-
ment, and explore the feasibility of collecting the data and
follow-up of participants to inform the sample size of a
definitive trial. A secondary aim was to test the concept
that an individually tailored assessment improves uptake
of lifestyle change compared with usual assessment. The
trial protocol has been published elsewhere [40].” We rec-
ommend putting detailed individual objectives into the
pilot trial report itself so that readers can more easily
judge the extent to which these have been fulfilled by the
study.
Inclusion of an objective to test a hypothesis of effect-
iveness (or efficacy) is not recommended (see Box 1).
However, other kinds of hypotheses may be tested, such
as when using an interim or surrogate outcome to ad-
dress potential effectiveness [41]. (See also the section
entitled Scope of this paper). However, a trial should al-
ways be adequately powered for any hypothesis test, and
in a pilot trial it should be clearly stated that the object-
ive is to assess potential effectiveness. If tests are carried
out without adequate power (as they sometimes are in
reality), they should certainly be viewed as secondary
and a caveat included in the discussion [21].
Methods
- Item 3a
- Standard CONSORT item: description of trial design
(such as parallel, factorial) including allocation ratio
- Extension for pilot trials: description of pilot trial de-
sign (such as parallel, factorial) including allocation ratio
- Example
“We conducted a parallel-group randomised controlled
pilot trial… An unequal randomisation of 2:1 vs 1:1 was
chosen to provide experience delivering the hydration
intervention to more patients [42].”
Eldridge et al. Pilot and Feasibility Studies  (2016) 2:64 Page 11 of 32
- Explanation
The design of any study should be described, be it a
definitive trial or a pilot trial. It is not uncommon for
pilot trials to adopt ratios other than the usual 1:1 for
randomisation. 1:1 randomisation provides the greatest
power for testing effectiveness in, for example, a future
definitive RCT. However, a pilot trial commonly involves
new, not established, interventions and one of the aims
might then be to gain experience in delivering the inter-
vention, in which case it is often better to have as many
participants receiving the intervention as is feasible.
- Item 3b
- Standard CONSORT item: important changes to
methods after trial commencement (such as eligibility
criteria), with reasons
- Extension for pilot trials: important changes to
methods after pilot trial commencement (such as eligi-
bility criteria), with reasons
- Example
“After randomly assigning 11 patients (5 to standard
care), we recognized that patients assigned to standard
care were receiving early surgery because, having
achieved accelerated medical clearance, they were put
on the operating room list. We therefore amended the
protocol to randomly assign patients immediately on
diagnosis; only those assigned to early surgery received
an expedited medical assessment [43].”
- Explanation
Pilot trials are exploratory and so those conducting them
should be able to modify the methods if a potential prob-
lem becomes apparent. In the case of Buse et al. [43], the
original protocol specified that patients had to have med-
ical clearance for rapid surgery before randomisation, but
this led to contamination of the control group as some pa-
tients in this group were put on the surgical list for rapid
surgery (accelerated surgery was the intervention) because
it had been ascertained that they were suitable candidates.
In the revised protocol participants were randomised first
and then assessed for suitability to accelerated access. Thus
the pilot potentially improved the design of the trial that
was to follow. It is important to document all changes and
give reasons for the changes. The example describes
changes to the timing of randomisation, but there might
also be changes to other aspects of the trial, such as the
treatment regimen, eligibility criteria, or outcome variables.
- Item 4a
- Standard CONSORT item: eligibility criteria for
participants
- Example
“Thirty-one sequential eligible people with HD
[Huntington’s disease] were recruited from the
specialist HD clinics in Cardiff, the United Kingdom,
and Oxford, the United Kingdom, between March
2011 and November 2011. Inclusion criteria were (1)
diagnosis of HD, confirmed by genetic testing and
neurological examination, (2) ability to walk
independently as primary means of mobility, (3)
willing to travel to the exercise center for the
intervention, (4) capacity to give informed consent,
(5) Unified Huntington’s Disease Rating Scale Total
Motor Score (UHDRS-TMS) and Total Functional
Capacity (TFC) of at least 5/124 and 5/13, respectively,
from last clinic visit, and (6) maintenance of a stable
medical regimen for 4 weeks prior to initiation of study
and considered by the recruiting clinician as able to
maintain a stable regimen for the course of the study.
Participants were not eligible if they (1) had a history of
additional prior major neurological condition such as
stroke, (2) had an orthopedic condition that limited
mobility, (3) demonstrated uncontrolled psychiatric
symptoms, (4) were pregnant, (5) demonstrated any
contraindication to exercise, or (6) were involved in any
interventional trial or within 3 months of completing
an interventional trial [44].”
- Explanation
Readers might want to know how the results of the
trial are likely to apply to the future definitive RCT and
other future trials with similar participants in similar set-
tings. A variety of participants (eg, patients, doctors, as-
sessors, caregivers, managers) might provide data to
address objectives. For example, in a study in nursing
homes, residents were interviewed to seek views on ac-
ceptability of the intervention, whereas nurses participated
in focus groups to elicit views on randomisation or adher-
ence to treatment protocol [32]. Eligibility criteria should
be specified for each set of participants included in a pilot
trial. The details provided must be specific enough to
identify the clinical population and any other populations
and the setting from which they were recruited and to
confirm that legal issues were complied with, such as
having capacity to give informed consent. Details should
be sufficient to allow other researchers to interpret, learn
from, and use the information provided.
- Item 4b
- Standard CONSORT item: settings and locations
where the data were collected
- Example
“High-risk adolescents were recruited from three
sources: (1) a sample of 205 offspring of BP parents
between 12 and 18 years of age enrolled in the NIMH-
funded Bipolar Offspring Study at the University of
Pittsburgh (BIOS, PI: Birmaher); (2) offspring of adults
receiving treatment for BP at Western Psychiatric
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Institute and Clinic (WPIC); and (3) siblings of youth
receiving treatment for BP at the Child and Adolescent
Bipolar Services clinic (CABS) at WPIC [45].”
- Explanation
The settings for recruiting patients and collecting data
must be specified so that readers can judge the applic-
ability (generalisability) of the findings to other trials as
well as to the future definitive RCT. Authors should
also make clear whether any pilot sites have particular
features—for example, organisational features, charac-
teristics that predispose the site to early adoption of
new schemes, or specific relationships with the authors
that could affect recruitment, consent, and follow-up.
This is because these features may not be replicable in
other sites and hence in future trials. As with item 4a,
details must be sufficient to allow other researchers to
interpret, learn from, and use the information.
- Item 4c
- Extension for pilot trials: how participants were
identified and consented
- Example
“Between May and October 2013, clinical staff at
participating gastroenterology outpatient clinics
scanned and identified potential participants that met
the study inclusion criteria. Then, either study
invitation packs were sent to patients with researchers’
contact details or patients seen consecutively in clinics
were approached with the study information. All study
information was co-designed with patients from the pa-
tient-involvement group. Interested participants then
registered their interest with the researcher by tele-
phone or email. This was followed up with a screen-
ing visit with the researcher and then informed
written consent was obtained [46].”
- Explanation
This is a new item. It is especially important to report
details of identification and consent in a pilot trial to
allow the feasibility of the recruitment methods to be
assessed. The way participants are identified and
approached should be described in detail (eg, by adver-
tisement, or selection from medical records or another
dataset) to enable readers to understand the generalis-
ability (applicability) of the results. This might be of
particular importance for scaling-up for the future de-
finitive RCT, as well as being informative for other fu-
ture trials. In addition, it is important to know of any
specific aspects that might not be easy to implement in
the future definitive RCT. Furthermore, a view is some-
times held that pilot trials do not need to be as rigorous
in their processes as other trials, so it might be particu-
larly important in these trials to show rigorous and
ethical identification and recruitment processes. If de-
tails of the way participants were identified and consent
obtained are already published in a protocol, then this
should be clearly referenced.
- Item 5
- Standard CONSORT item: the interventions for each
group with sufficient details to allow replication, includ-
ing how and when they were actually administered
- Example
“Intervention (EXERcise or STRETCHing)
The amount of time required for participating in the
exercise activities was the same for the EXER group
and the STRETCH group. The only difference was the
amount of energy expended during the activity. At the
first session, the exercise trainer explained the
procedures for the respective intervention (EXER or
STRETCH), showed them the equipment available for
the exercise or stretch sessions, and the coordinator
familiarized the participant with the Actical device.
The first two weeks required a minimum of 3 sessions
at CI [Cooper Institute] for the trainer to teach them
how to use the equipment and complete the exercise
or stretch routines. Following the first 2 weeks,
participants began doing their exercise program at
home or other location (gym, park, etc.), and only had
to come to CI once a week for an exercise session. Each
EXER/STRETCH session averaged about 30–40 min.
EXERcise Intervention
Supervised exercise sessions at the Cooper Institute
(CI) for the participants began by using the treadmills
or stationary cycles. The CI trainers also taught
patients how to complete home-based exercise sessions
(e.g., choice of Wii Sports and Fit, jazzercise, jogging,
weight training based on their preferred exercise) that
were unsupervised workouts at the patient's home or in
the community. The duration of each session generally
was the time required to reach 1/3 or 1/4 of the total
weekly caloric expenditure. There was a progression
to the assigned exercise dose in the first few weeks
that got them up to their minimum of 12 kilocalories/
kilogram/week (KKW) energy expenditure (e.g., 8 KKW
first week, 10 KKW second and 12 KKW by the third
week). Participants exercised three times per week.
STRETCH Intervention
The stretch group spent approximately the same
amount of time, but at energy expenditures of less
than 4 KKW per session. After two weeks of three
sessions at CI they moved to once a week at CI and
two home-based sessions. A 5–10 minute stretching
warm-up period included stretches that exercise the
major muscle groups of the body. The series included
such traditional “warm-up” stretches as: stretches of
Eldridge et al. Pilot and Feasibility Studies  (2016) 2:64 Page 13 of 32
the gluts, inner thigh, calves and ankles, Achilles
tendon, hamstring stretches, shoulder rolls forward
and back, shoulder shrugs, isometrics for the neck
hugging knees into the chest, moving forehead to
right knee, then to left, then to both, and use of the
pelvic tilt. An additional 10–15 minutes consisted of
moving on to right and left calf stretches, quad
stretches, and then to a series for the arms, hands,
fingers, wrist, biceps/triceps, shoulders and back. All
of the exercises were designed to be done slowly,
emphasizing proper alignment, and rest periods to
minimize overall physical exertion while obtaining
general flexibility, and most importantly controlling
for contact time with trainers and any social facilitation
from participating in such activities. We had a different
set of low level/low intensity routines for each of the
12 weeks to minimize boredom with the routines [47].”
- Explanation
If the pilot trial is to inform future research, the au-
thors should report exact details of the treatment given
to all study groups, and if one group receives treatment
as usual this should also be described thoroughly. Details
should include who administered the treatment, as well
as what it comprised and how often and where it was
delivered. The template for intervention description and
replication (TIDieR) guidelines should be followed and
the checklist completed [48]. If there are changes to the
details of the treatments for any group, these must be
reported (see item 3b).
- Item 6a
- Standard CONSORT item: completely defined pre-
specified primary and secondary outcome measures, in-
cluding how and when they were assessed
- Extension for pilot trials: completely defined prespe-
cified assessments or measurements to address each
pilot trial objective specified in item 2b, including how
and when they were assessed
- Example
“Acceptability and demand were assessed in terms of
the usage and repeated usage of the intervention by
the patients in the trial indicated by logged user
statistics. The interventions’ practicability was
considered as the ability to log in and occurrence of
constraints in delivery and was assessed in terms of the
percentage of users in adolescents and professionals, its
bounce percentage (percentage of login-errors) and other
login-problems. The bounce-percentage was logged and
participants were asked to report login-errors. Integration
was assessed in terms of the extent to which our
web-based intervention promotes care that was
consistent with recognized standards of diabetes care
for adolescents including those published by the
International Diabetes Federation (IDF) in collaboration
with the International Society for Pediatric and
Adolescent Diabetes (ISPAD) and the American
Diabetes Association (ADA; 3, 33); see also Appendix 1
[49].”
- Explanation
In a definitive trial investigators are primarily interested
in response variables or outcomes that enable them to fulfil
the primary objective (to assess the effect of an interven-
tion or treatment), and a clear articulation of prespecified
outcomes is required to guard against bias in the assess-
ment of this effect. In a pilot trial, however, objectives
should relate to feasibility (see Box 1 and item 2b) and any
measurements or assessments should enable these objec-
tives to be addressed. To ensure the pilot trial meets its ob-
jectives, measures or assessments should be defined to
address each separate objective or research question. In the
example, objectives were to assess acceptability, demand,
practicability, and integration. The authors list the mea-
sures used for each of these.
Variables that might be considered primary and second-
ary outcomes for the future definitive RCT might be mea-
sured in a pilot trial to assess response, completeness, or
validity. The appropriate measures or assessments would
then be response rates, completion rates, or measures of
validity. Sometimes investigators may want to measure
surrogate outcomes (see example in item 7b), variables on
the causal pathway of what might eventually be the pri-
mary outcome in the future definitive RCT, or outcomes
at early time points, in order to assess the potential for the
intervention to affect likely outcomes in the future defini-
tive RCT (see item 2b).
- Item 6b
- Standard CONSORT item: any changes to trial out-
comes after the trial commenced, with reasons
- Extension for pilot trials: any changes to pilot trial as-
sessments or measurements after the pilot trial com-
menced, with reasons
- Example 1 (change to assessment time period)
“Our outcome measures examined uptake and
cessation because we hoped that our intervention
would affect uptake by referring more people and the
success rate of those referred by supporting adherence
to treatment…The intervention had two distinct
phases so, although not planned in the protocol, we
examined uptake of services and 4-week quit rates by
trial arm, in these two periods [50].”
- Example 2 (change to measurement instrument)
“We defined…initiation of change as participation in a
formal program or a self-directed program that was
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intended to result in change either in diet, physical ac-
tivity, smoking, or alcohol consumption at any time
(binary)…In our published protocol, we had proposed
4 categories of change, but we found it difficult to
distinguish between “persisted” and “maintained” in
the qualitative follow-up interviews; hence, we
combined persistence and maintenance of change in
1 category [40].”
- Explanation
An assessment or measure might change during a pilot
trial because the change enables investigators to glean
more information about the operation of the interven-
tion (as in example 1) or for reasons of acceptability or
practicability (example 2). In example 2 it became im-
practical to use a measurement instrument with four
categories when it was identified that researchers could
not distinguish between two of the categories. In the in-
terests of full reporting and because of the usefulness of
such information to others working in the same spe-
cialty, all such changes should be reported.
- Item 6c
- Extension for pilot trials: if applicable, prespecified
criteria used to judge whether, or how, to proceed with
future definitive trial
- Example
“Feasibility (delivery) and acceptability (uptake) of the
DECISION+ program were the main outcome
measures of this pilot trial. Investigators had
established a priori threshold for specific feasibility
and acceptability criteria. These were the following:
(a) the proportion of contacted FMGs [Family
medicine groups] participating in the pilot study
would be 50 % or greater, (b) the proportion of
recruited family physicians participating in all three
workshops would be 70 % or greater, (c) the mean
level of satisfaction from family physicians regarding
the workshops would be 65 % or greater, and (d) the
proportion of missing data in each completed
questionnaire would be less than 10 % [34].”
- Explanation
This is a new item. The purpose of a pilot trial is to assess
the feasibility of proceeding to the next stage in the re-
search process. To do this investigators need some criteria
on which to base the decision about whether or not to
proceed. The next stage in the research process will nor-
mally, although not always, be the future definitive RCT.
The UK National Institute for Health Research requires
that pilot or feasibility studies have clear criteria for decid-
ing whether or not to progress to the next stage: “We ex-
pect that when pilot or feasibility studies are proposed by
applicants, or specified in commissioning briefs, a clear
route of progression criteria to the substantive study will
be described. Listing clear progression criteria will apply
whether the brief or proposal describes just the prelimin-
ary study or both together. Whether preliminary and main
studies are funded together or separately may be decided
on practical grounds [51].”
In many pilot studies, however, such criteria may be
best viewed as guidelines rather than strict thresholds
that determine progression. In the example, the authors
found that only 24 % of the family medicine groups
(FMGs) agreed to participate. They state “Not reaching
the pre-established criteria does not necessarily indicate
unfeasibility of the trial but rather underlines changes to
be made to the protocol” [34]. Clearly it is important to
discuss whether such changes to protocol are likely to
be feasible, and this discussion might often benefit from
input independent of the trial team—for example, from
the trial steering committee. This would be a reason for
having such a committee in place for a pilot trial. Bugge
et al. recently provided further guidance on decision
making after a pilot trial [52].
In addition to the possibility of making changes to the
trial protocol, investigators should also be aware that es-
timates of rates in pilot trials may be subject to consider-
able uncertainty, so that it is best to be cautious about
setting definitive thresholds that could be missed simply
due to chance variation [41]. In fact it is becoming in-
creasingly common for investigators to use a traffic light
system for criteria used to judge feasibility, whereby
measures (eg, recruitment rates) below a lower threshold
indicate that the trial is not feasible, above a higher
threshold that it is feasible, and between the two that it
might be feasible if appropriate changes can be made.
- Item 7a
- Standard CONSORT item: how sample size was
determined
- Extension for pilot trials: rationale for numbers in
the pilot trial
- Example 1 (rationale based on assessment of practi-
calities and estimating rates)
“Since this was a pilot study, a sample size calculation
was not performed. The researchers aimed for 120
participants because it was felt this would be a large
enough sample to inform them about the practicalities
of delivering several self- management courses led by
patients with COPD, recruitment, uptake, and
attrition [53].”
- Example 2 (rationale based on percentage of number
required for future definitive RCT)
“As this is a feasibility study a formal sample size
calculation is not required, but we estimated the
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number of participants required as around 10 % of
the number required for the Phase 3 trial. The sample
size calculation for the Phase 3 trial suggests we need
to recruit 1665 participants. Given the participant
population, a high level of attrition may be anticipated.
We therefore aim to recruit 200 participants to the
feasibility trial to inform the design and sample size of
the Phase 3 RCT [54].”
- Explanation
The criterion of congruency between the objectives
and the sample size holds as true for a pilot trial as for
any study. Many pilot trials have key objectives related
to estimating rates of acceptance, recruitment, retention,
or uptake (see item 2b for examples). For these sorts of
objectives, numbers required in the study should ideally
be set to ensure a desired degree of precision around the
estimated rate, although in practice it may be difficult to
achieve these numbers. Additionally, for pilot trials
where the key objective focuses on the acceptability or
feasibility of introducing the intervention, it might be
useful to consider how many sites are needed, as the ac-
ceptability or feasibility of introduction can sometimes
depend on the site. In example 1, the authors state their
reason for choosing their required sample size in rela-
tion to estimating rates and to exploring practicalities of
implementing the intervention. They could, however,
have provided stronger justification for their chosen num-
ber, such as likely recruitment or attrition rate and desired
precision around these rates, so that the reader (and
funder) has more grounds for believing the trial could
achieve its objectives beyond a feeling.
Most methodological papers that focus on recommen-
dations about sample size requirements for pilot trials
assume that the main aim of such a trial is to estimate a
quantitative measure such as the variance (or standard
deviation) of an effect size to inform the sample size cal-
culation for a future definitive RCT. Methods focus on
the precision with which such estimates can be obtained.
There are several relevant papers [55–57]. Among these,
Whitehead et al. suggests that the size of a pilot trial
should be related to the size of the future definitive RCT
[58]. For such a trial designed with 90 % power and two
sided 5 % significance, they recommend pilot trial sam-
ple sizes for each treatment arm of 75, 25, 15, and 10 for
standardised effect sizes that are extra small (0.1), small
(0.2), medium (0.5), or large (0.8), respectively.
Example 2 illustrates another approach that uses a
sample that is a certain percentage of the expected size
of the future definitive RCT. The authors reference the
paper by Cocks and Torgerson, which is based on using
a sample size under which a one sided 80 % confidence
interval for the effect size will exclude the minimum
clinically important difference if the null hypothesis is
true [59]. This is a similar calculation to that used in es-
timating sample size needed for efficacy or effectiveness
but allows for additional uncertainty in the resulting
effect size estimate, thus effectively assessing potential
effectiveness. If an objective is to assess potential ef-
fectiveness using a surrogate or interim outcome, investi-
gators will need to use a standard sample size calculation
to ensure there is adequate power. However, this type of
objective is rare in pilot trials.
- Item 7b
- Standard CONSORT item: when applicable, explan-
ation of any interim analyses and stopping guidelines
- Example
“The board members were instructed to perform an
interim analysis after 60 patients had been enrolled, at
which point they could recommend stopping the trial
if an overwhelming effect was detected on the basis of
the critical significance level (P ≤ 0.02), as adjusted for
the Lan– DeMets alpha-spending function with
Pocock boundary” [20]
- Explanation
As pilot trials are small, it is uncommon for them to
define criteria for early stopping, but if they do, these
should be reported. The example is a pilot trial testing a
surrogate outcome. There was considerable uncertainty
about the variability of this outcome measure, and so
the authors calculated a conservative sample size but in-
cluded an interim analysis after recruiting 60 patients, in
case their a priori estimates were too large and they had
enough information at that stage to inform subsequent
trials.
- Item 8a
- Standard CONSORT item: method used to generate
the random allocation sequence
- Example
“Participants were randomly allocated to the
intervention ‘MBCT group’ or ‘wait-list control group’…
Random allocation was computer generated [46].”
- Explanation
Randomisation induces unpredictability in the alloca-
tion of each unit of randomisation. This is an important
element of ensuring an unbiased treatment effect in
RCTs evaluating effectiveness or efficacy because in the
long run it ensures balance in characteristics between
intervention groups. In a pilot trial, the soundness of the
randomisation method might not directly influence ro-
bustness of the pilot trial results, which are not focused
on estimates of effectiveness or efficacy, but a clear de-
scription of the process of randomisation is still import-
ant for transparent reporting.
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In addition, in some pilot trials one of the objectives
might be to assess the feasibility of randomisation; it is
also important, therefore, that details are reported. If
assessing feasibility involves more than one method be-
ing used to generate a random allocation sequence, each
method should be described adequately.
- Item 8b
- Standard CONSORT item: type of randomisation; de-
tails of any restriction (such as blocking and block size)
- Extension for pilot trials: type of randomisation(s); de-
tails of any restriction (such as blocking and block size)
- Example 1 (example with blocking)
“Participants were randomised in block sizes of three
by computer-generated randomisation to the hydra-
tion group or the control group (2:1), stratified by
gender [42].”
- Example 2 (two different types of randomisation)
“In addition to random allocation to one of the three
treatment arms, we used a 2 × 2 factorial design to
distribute practices and participants across two trial
design factors: cluster versus individual allocation and
systematic versus opportunistic recruitment (see
Fig. 1). We randomly assigned 24 practices (8
practices in each of 3 geographical regions (Bristol,
Devon and Coventry)) in a 3:1 ratio to cluster
(practice) allocation or individual allocation, and in a
1:1 ratio to opportunistic or systematic recruitment.
The differential allocation ratio with regard to
randomisation method was due to the need to ensure
even numbers of practices and participants in each of
the three arms across the cluster randomised
practices [60].”
- Explanation
The type of randomisation, including whether simple
or restricted, should be reported.
For practical reasons simple randomisation is some-
times used in pilot trials even when restricted random-
isation is expected to be used in the future definitive
RCT, and if this is the case this needs to be described.
Restricted randomisation is particularly useful in small
trials evaluating the effectiveness of an intervention, to
ensure balance in certain characteristics between inter-
vention and control groups (see main CONSORT state-
ment) [2, 61]. In pilot trials, restricted randomisation
might be used to mimic the type of randomisation ex-
pected in the future definitive RCT or, if it is deemed
important, to have balanced groups even if restricted
randomisation is not expected to be used in the future
definitive RCT. In example 1, stratified randomisation,
employing blocking, was used.
One of the objectives of a pilot trial might be to assess
the feasibility of randomisation; it is therefore possible
that different types of randomisation could be tried, as
in example 2 where cluster versus individual randomisa-
tion was considered [60].
- Item 9
- Standard CONSORT item: mechanism used to imple-
ment the random allocation sequence (such as sequen-
tially numbered containers), describing any steps taken to
conceal the sequence until interventions were assigned
- Example
“Allocation…was implemented using an automated
telephone randomization service provided by the
Bristol Randomized Trials Collaboration to ensure
concealment from clinical staff undertaking
recruitment [62].”
- Explanation
Ensuring allocation concealment is a cornerstone of a
good randomised trial design. This mechanism performs
a key function in minimising bias by preventing fore-
knowledge of treatment assignment, which could influ-
ence those who enrol participants. In a future definitive
RCT a single mechanism will be used to conceal alloca-
tion. However, in a pilot trial the main purpose of using
an allocation concealment mechanism is to establish the
feasibility of the mechanism. If there is considerable un-
certainty about the mechanism to be used, more than
one mechanism may be tried in the pilot trial. We would
expect this to be rare, but when it does occur the details
of each mechanism tried should be fully described.
- Item 10
- Standard CONSORT item: who generated the ran-
dom allocation sequence, who enrolled participants, and
who assigned participants to interventions
- Example 1 (who generated the random allocation
sequence)
“An independent statistical consultant set up the
web-based randomization process to assign eligible
participants to intervention or control groups by
remote allocation, using permuted blocks of sizes 2
and 4. No one directly involved in the project had
access to allocation codes [21].”
Example 2 (who enrolled participants, who assigned
participants to interventions)
“Eligible children and their families were identified by
the clinician conducting the assessment. If the child
and his or her family were willing to find out more
about the study a researcher contacted the family and
arranged to visit them at a convenient location
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(usually at home)…Those willing to take part were
randomized to receive either specialist medical care
or to specialist medical care plus the Phil Parker
Lightning Process (LP). Allocation…was
implemented…by the Bristol Randomized Trials
Collaboration…” [62]
- Explanation
It is important that the pilot trial confirms that alloca-
tion concealment can be implemented in a way that
could be replicated in the future definitive RCT. This in-
volves knowing who generated the randomisation se-
quence and who enrolled and assigned participants.
- Item 11a
- Standard CONSORT item: if done, who was blinded
after assignment to interventions (eg, participants, care
providers, those assessing outcomes) and how
- Example 1 (blinding of multiple people)
“Patients, families, ICU [intensive care unit] staff,
ultrasound technologists, and research personnel were
all blinded to drug allocation. The study pharmacist at
each center was the only person who was not blinded
[63].”
- Example 2 (placebo controlled)
“A synbiotic formulation (Synbiotic 2000®) containing
4 strains of probiotic bacteria (1010 each) plus 4
nondigestible, fermentable dietary fibers (2.5 g each)
was provided each day, versus a fiber-only placebo
formulation [64].”
- Explanation
In the future definitive RCT investigators will want to
reduce the chance of a biased result as much as possible.
Blinding is seen as one of the most effective ways of
doing this, at least in trials where blinding is feasible
(see main CONSORT statement for details). The main
purpose of a pilot trial is to assess the feasibility of
methods, including those to reduce bias. In some pilot
trials it might be useful to report the method of blinding
in detail, as in example 2, to help readers who might
want to replicate the method in future RCTs.
It is tempting in a pilot trial to try and assess the suc-
cess of blinding by asking people whether they believed
they were blinded or not. This was done, for example in
Arnold et al. [65]. This is not recommended, however,
because evidence suggests that results of doing this largely
reflects the effectiveness of the intervention rather than
anything else [66].
- Item 11b
- Standard CONSORT item: if relevant, description of
the similarity of interventions
- Example
“Each study drug infusion was administered using a
standard volume-based rate escalation protocol
preceded by the administration of 100 mg of
hydrocortisone intravenously, 50 mg of diphenhydramine
orally or intravenously, and 650 mg of acetaminophen
orally to minimize infusion-related reactions and avoid
unblinding [65].”
- Explanation
If blinding is done by creating a placebo, it is import-
ant in trials assessing the effect of an intervention to de-
tail what features of the placebo were made similar to
the active intervention (usually a drug)—for example,
appearance, taste, smell, method of being administered.
However, many of the interventions described in pilot
trials are not drug interventions. Nevertheless, it remains
important to describe what was done to try and ensure
that the intervention and control arms received identical
treatment aside from the active ingredient where this
is possible. It is equally important to note that for
complex interventions it might not be possible or feas-
ible to blind certain people to allocation using these
types of methods.
- Item 12a
- Standard CONSORT item: statistical methods used
to compare groups for primary and secondary outcomes
- Extension for pilot trials: methods used to address
each pilot trial objective whether qualitative or quantitative
- Example 1 (descriptive and narrative reporting)
“The feasibility outcomes were reported descriptively
and narratively. For the clinical endpoints, only
descriptive statistics, mean (standard deviation) for
continuous outcomes and raw count (%) for categorical
outcomes, were reported [67].”
- Example 2 (confidence intervals)
“For the primary outcomes, the feasibility criteria
were the recruitment rate and duration, retention
rate, safety, adverse events, compliance,
acceptability of the interventions and fatigue…The
recruitment rate, consisting of the eligibility and
consent rate, was calculated with 95 % CI…Medians
(range) were reported for ordinal data (fatigue),
mean (95 % confidence interval (CI)) were reported
for continuous data (walking speed and walking
distance) and raw count (number, %) was reported
for nominal data. Due to the nature of this
feasibility study, it was decided not to conduct any
efficacy statistical tests on the walking and fatigue
data [68].”
Eldridge et al. Pilot and Feasibility Studies  (2016) 2:64 Page 18 of 32
- Explanation
A range of methods can be used to address the objec-
tives in a pilot trial. These need not be statistical. Provid-
ing information about the methods used ensures that
findings can be verified on the basis of the description of
the analyses used. The primary focus is on methods for
dealing with feasibility objectives. These methods are often
based on descriptive statistics such as means and percent-
ages but might also be narrative descriptions (example 1).
Typically, any estimates of effect using participant out-
comes as they are likely to be measured in the future
definitive RCT would be reported as estimates with
95 % confidence intervals without P values—because
pilot trials are not powered for testing hypotheses about
effectiveness.
- Item 12b
- Standard CONSORT item: methods for additional
analyses, such as subgroup analyses and adjusted analyses
- Extension for pilot trials: not applicable
- Explanation
In a definitive trial, analyses of a difference in treatment
effect for subgroups or analysis of outcomes adjusted for
baseline imbalance might provide useful information.
However, such analyses in a pilot trial are not applicable
because the primary focus is not on determining treat-
ment effects or differences in effects between subgroups.
Rather, the focus is on assessing feasibility or piloting pro-
cedures to inform the design of the future definitive RCT.
Results
- Item 13a
- Standard CONSORT item: for each group, the num-
bers of participants who were randomly assigned, received
intended treatment, and were analysed for the primary
outcome
- Extension for pilot trials: for each group, the numbers
of participants who were approached and/or assessed for
eligibility, randomly assigned, received intended treatment,
and were assessed for each objective
- Example
See Figs. 4 and 5 [2, 69].
- Explanation
As for other trials, we recommend a diagram for com-
municating the flow of participants in a pilot trial. A
flow diagram is a key element of the CONSORT state-
ment and has been widely adopted [70]. A review of
RCTs published in five leading general and internal
medicine journals found that reporting was considerably
more thorough in articles that included a diagram of the
flow of participants through a trial, as recommended by
CONSORT [70]. A complete CONSORT flow diagram
also reduces the time for readers to find essential infor-
mation to assess the reliability of a trial. It is also likely
to improve the availability of some information that
otherwise might not be reported.
Information required to complete a CONSORT flow
diagram includes the number of participants evaluated
for potential enrolment into the trial and the numbers of
participants who were randomly assigned to each inter-
vention group, received treatment as allocated, completed
treatment as allocated, and were analysed for the primary
outcome, with numbers and reasons for exclusions at each
step [2, 61].
For pilot trials it might also be important to know the
number of participants who were approached (or screened)
before being assessed for eligibility for potential enrolment
into the trial. This ensures that readers can assess external
validity and how representative the trial participants are
likely to be compared with all eligible participants [71].
Additionally, for pilot trials it is important to know how
many participants were approached before being evaluated
for potential enrolment in the trial and how easy it was to
recruit them, in order to assess the potential for enrolment
for the future definitive RCT and other future trials. In
some cases where these elements are a major focus of a
pilot trial more information may be needed in the flow dia-
gram (Fig. 4).
For pilot trials it is appropriate to report the number
of participants assessed for each pilot trial objective, ra-
ther than the number analysed for the primary outcome
(as would be the case for the future definitive RCT). If
there are a limited number of objectives in the pilot trial
then all should be listed and results for each objective
reported in the flow diagram. If there are multiple objec-
tives, then agreement should be reached a priori about
which are the most important to decide whether to
proceed to a future definitive RCT, and only these objec-
tives should be reported in the flow diagram. Figure 5
provides a template for a CONSORT flow diagram for
pilot trials, including presentation of results for different
objectives. The exact form and content might, however,
vary in relation to the specific features of the trial. Au-
thors should ensure that their flow diagram matches the
key objectives as far as possible.
- Item 13b
- Standard CONSORT item: for each group, losses and
exclusions after randomisation, together with reasons
- Example
“All 16 patients randomised to the Symptoms Clinic
attended the first appointment and 11 completed
either three or four appointments. Of the remainder,
two were clearly improving at the time they were seen
and agreed to early discharge; two found further
attendance difficult after a second appointment and one
declined any further contact after the first appointment.
Several patients randomised to usual care expressed
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  Did not receive allocated intervention
  Did not receive allocated intervention
Enrolment
Allocaton Allocaton
Interim analysis Interim analysis
Fig 4 Flow diagram of a randomised pilot trial of pharmacist led management of chronic pain in primary care (reproduced from Bruhn et al [69])
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some disappointment at the time of their allocation,
although follow-up response rates were comparable
between the two groups [72].”
- Explanation
For some RCTs the flow of participants through each
phase of the trial can be relatively straightforward to de-
scribe, particularly if there were no losses to follow-up
or exclusions. However, in more complex trials, it might
be difficult for readers to identify whether and why some
participants did not receive the treatment as allocated,
were lost to follow-up, or were excluded [73]. In a de-
finitive trial this information is crucial for interpreting
generalisability, as participants who are excluded after
allocation are unlikely to be representative of all partici-
pants in the study [74]. In a pilot trial, this information
could be used to judge potential generalisability of the
future definitive RCT but also to assess the acceptability
of an intervention to participants and to aid planning of
the future definitive RCT and other trials in similar
settings.
- Item 14a
- Standard CONSORT item: dates defining the periods
of recruitment and follow-up
- Example
“Patient enrolment started in August 2003 and was
completed in October 2005 [75].”
- Explanation
It is important to report dates for all studies for trans-
parency. An added rationale for pilot trials is that factors
such as disease definitions, treatment options, and reim-
bursement plans that could affect the future definitive
RCT might have changed between the date that the pilot
trial was conducted and the date the future definitive
RCT starts. The availability of different treatments out-
side the trial can also change and might make a difference
to people’s willingness to be randomised. Thus recruit-
ment to a pilot trial could be easier, or more difficult, than
recruitment to the future definitive RCT. In addition,
knowing the length of time over which the study took
place might be important for planning the future defini-
tive, and other, RCTs.
- Item 14b
- Standard CONSORT item: why the trial ended or
was stopped
- Extension for pilot trials: why the pilot trial ended or
was stopped
- Example 1 (stopped without reaching intended
recruitment but provided sufficient data)
Allocated to intervention (n=):
  Received allocated intervention (n= )
  Did not receive allocated intervention
    (give reasons) (n= )
Allocated to intervention (n=):
  Received allocated intervention (n= )
  Did not receive allocated intervention
    (give reasons) (n= )
Screened prior to eligibility assessment (n= )
Assessed for eligibility (n= )
Randomised (n= )
Lost to follow-up (give reasons) (n= )
Discontinued intervention (give reasons) (n= )
Lost to follow-up (give reasons) (n= )
Discontinued intervention (give reasons) (n= )
Etc. Etc.
Excluded (n= ):
  Reasons (n= )
Excluded (n= ):
  Not meeting inclusion criteria (n= )
  Declined to participate (n= )
  Other reasons (n= )
Screened
Enrolment
Allocation
Follow-up
Assessment
Fig 5 Recommended flow diagram of progress through phases of a parallel randomised pilot trial of two groups—that is, screening, enrolment,
intervention allocation, follow-up, and assessed for each pilot trial objective. Adapted from Moher et al [2]
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“Enterotoxigenic Escherichia coli (ETEC) is a major cause
of travellers’ diarrhoea…We designed this phase II,
double-blind, randomised placebo-controlled study to
investigate the epidemiology of natural infection with
ETEC in placebo recipients with a planned enrolment of
300 individuals, at a placebo-to-LT patch ratio of 2:1…
The study was halted when enrolment reached 201,
because the planned interval for conduct had been
exceeded, and it was thought that a placebo group greater
than 100, although less powerful than the original 200,
would be sufficient to assess the ETEC attack rate in pla-
cebo recipients…24 (22 %) of 111 placebo recipients had
diarrhoea, of whom 11 (10 %) had ETEC diarrhoea [76].”
- Example 2 (stopped at end of recruitment but did not
provide sufficient data)
“Recruitment rates were lower than expected which
led to the study being expanded to further areas and
opened to self-referral via advertisement. However,
because of better management of hypertension due to
changes in the UK Quality and Outcomes Framework
guidelines for blood pressure treatment, few eligible
patients were identified and the study closed at the
end of the recruitment period, with 13 participants
consenting, but 12 failing screening resulting in one
recruited participant [77].”
- Explanation
When pilot trials end or are stopped, it is important to
state why as this might affect the feasibility of the future de-
finitive RCT. In example 1 the investigators had run out of
time and thought they would have sufficient participants to
estimate the rate of diarrhoea so as to inform future studies.
It is not uncommon for changes in the clinical environment
to occur, leading to fewer patients with unmanaged disease,
and this can lead to major studies, not just pilot studies,
failing to recruit. This illustrates a benefit of a pilot study to
assess the likely accrual for a future definitive RCT. In ex-
ample 2 the reason for stopping was simply a failure to re-
cruit, and the reasons for this are clearly stated. Other
potential reasons for stopping include the intervention be-
ing impossible to implement, other studies indicating that
the research has become irrelevant, and difficulties with
funding. It is also helpful to know who made the decision
to stop early. In definitive RCTs a data monitoring commit-
tee often makes recommendations to stop the trial. It might
not be necessary to have data monitoring committees for
all pilot trials, but investigators should give some thought
as to how the decision to stop should be made.
- Item 15
- Standard CONSORT item: a table showing baseline
demographic and clinical characteristics for each group
- Example
See Table 4.
- Explanation
In an RCT evaluating the effect of an intervention, a table
of baseline characteristics is important to indicate any dif-
ferences between intervention groups that could affect the
face validity of the trial. In a pilot trial, the number of par-
ticipants is likely to be smaller than in the future definitive
RCT and baseline imbalances might therefore be more
likely. Similar to a definitive trial, imbalance does not sug-
gest bias, and in any case bias is not a problem in the same
way it is in a definitive trial because an assessment of the ef-
fect of an intervention is not the primary concern. Never-
theless, baseline data are important to aid interpretation of
the results, including a consideration of generalisability, and
a table is the best way of presenting this information.
- Item 16
Standard CONSORT item: for each group, number of
participants (denominator) included in each analysis and
whether the analysis was by original assigned groups
- Extension for pilot trials: for each objective, number of
participants (denominator) included in each analysis. If
relevant, these numbers should be by randomised group
Table 4 Example of baseline information for each group. From Seebacher et al [68]
Parameter Group A Group B Group C
Music cued motor imagery Metronome cued motor imagery Control group
(n = 10) (n = 10) (n = 10)
Females to males 10:0 7:3 5:5
Age (years)a 47.3 (38.4, 56.2) 41.8 (34.8, 48.8) 46.1 (39.8, 52.5)
EDSSb 3 (1.5, 4.5) 2.5 (1.5, 4.5) 2.5 (1.5, 4.0)
MFIS total scoreb 35 (3, 67) 32 (17, 50) 33.5 (0, 48)
Participants with fatigue (MFIS total score ≥38) 4/10 2/10 4/10
T25FW (s)a 6.1 (4.5, 7.6) 5.4 (4.5, 6.2) 5.2 (4.3, 6.1)
6MWT (m)a 453.1 (365.0, 541.1) 428.2 (352.8, 503.6) 484.7 (399.5, 569.8)
EDSS Expanded Disability Status Scale, MFIS Modified Fatigue Impact Scale, T25FW Timed 25-Foot Walk, s seconds, 6MWT 6-Minute Walk Test, m metres
aMean (95 % confidence interval)
bMedian (range)
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- Example 1 (number of sites contacted)
“A research assistant made 41 introductory phone
calls to contact the medical directors of the 21 eligible
FMGs [family medicine groups] over a four-week period.
One director could not be contacted. Information
leaflets were faxed to the 20 contacted FMGs [34].”
- Example 2 (number of practitioners taking part
within sites)
“Out of the 52 eligible family physicians working in
the five participating FMGs [family medicine groups],
39 (75 %) agreed to participate in the study [34].”
- Explanation
In RCTs evaluating the effect of an intervention, out-
comes are usually measured on participants and there-
fore denominators are numbers of participants. However,
because of the potential variety of objectives in a pilot
trial, the denominators for measures that assess feasibility
according to these objectives might be organisations,
health practitioners, patients, or, in some cases, episodes
or events. In the interests of simplicity we have not
changed the word “participants” in this item, but the
item should be interpreted in the light of the particular
objective and associated measure or assessment. The
two examples are taken from the same trial. One ob-
jective was to assess the feasibility of recruitment. Par-
ticipants for that objective are FMGs (example 1) and
family physicians (example 2). The denominators of 21
(FMGs) and 52 (family physicians) indicate numbers
approached and therefore the effort involved in recruit-
ing. In this example providing numbers by randomised
group is not relevant.
- Item 17a
- Standard CONSORT item: for each primary and sec-
ondary outcome, results for each group, and the estimated
effect size and its precision (such as 95 % confidence
interval)
- Extension for pilot trials: for each objective, results
including expressions of uncertainty (such as 95 % confi-
dence interval) for any estimates. If relevant, these re-
sults should be by randomised group
- Example 1 (feasibility outcome)
“The ABSORB [A bioabsorbable everolimus-eluting
coronary stent system for patients with single de-novo
coronary artery lesions] study aimed to assess the
feasibility and safety of the BVS [bioasorbable
everolimus-eluting stent] stent in patients with single
de-novo coronary artery lesions…Procedural success
was 100 % (30/30 patients), and device success 94 %
(29/31 attempts at implantation of the stent) [78].”
- Example 2 (proposed outcome in future definitive
trial)
“Rates of initiation of lifestyle change also favoured
the individualized assessment arm but less clearly.
At 3 months, 75 % of the individualized assessment
arm and 68 % of the usual assessment arm had
initiated changes in their lifestyle (unadjusted odds
ratio, 1.38 [95%CI, 0.55 to 3.52]). At 6 months, the
percentages were 85 and 75 %, suggesting increased
initiation of change over time in both arms, with
the gap widening slightly (unadjusted odds ratio,
1.86 [95 % CI, 0.64 to 5.77])…Wide CIs again point
to the degree of uncertainty around this
conclusion” [40]
- Explanation
It is important that the reported results of a pilot
trial reflect the objectives. Results might include, for
example, recruitment, retention or response rates, or
other sorts of rates, as in example 1. Because the sam-
ple size in a pilot trial is likely to be small, estimates of
these rates will be imprecise and this imprecision
should be recognised, for example, by calculating a
confidence interval around the estimate. Commonly,
authors do not give such a confidence interval, but if
the numerator and denominator are given the confi-
dence interval can be calculated. In example 1 the Wil-
son 95 % confidence interval for 100 % (30/30) is 88.65
to 100 % and for 94 % (29/31) is 79.78 to 98.21 %
(OpenEpi Seattle) [78]. If authors do report differences
between trial arms (and this is not necessary if it is not
consistent with the objectives of the trial) then confi-
dence intervals again provide readers with an assess-
ment of precision (example 2), which usually indicates
considerable uncertainty. If samples in the pilot trial
and future definitive RCT are drawn from slightly dif-
ferent populations, confidence intervals calculated
from the pilot will not directly indicate the likely upper
and lower bounds of the relevant measure in the future
definitive RCT, but can nevertheless highlight the lack
of precision effectively.
- Item 17b
- Standard CONSORT item: for binary outcomes, pres-
entation of both absolute and relative effect sizes is
recommended
- Extension for pilot trials: not applicable
- Explanation
This item is included in the 2010 CONSORT statement
because when considering clinical implications, neither
the relative nor the absolute measures of effect size for
binary outcomes give a complete picture of the effect of
an intervention. For example, relative risks are less af-
fected by differences in baseline populations across studies
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than are absolute risks, although sometimes can be misin-
terpreted in terms of population benefit. In addition, dif-
ferent audiences (clinical, policy, patient) prefer to use one
or the other measure. However, in pilot trials the situation
is different. Because of the imprecision of estimates from
these trials and the fact that samples in these trials can be
unrepresentative (see item 17a), we caution against any re-
liance on estimates of effect size from pilot trials for clin-
ical implications (see also Introduction, Scope of this
paper, and Box 1). Information from outcome data, how-
ever, can be legitimately used for other purposes, such as
estimating inputs for sample size for the future definitive
RCT (see item 7a). Thus item 17b, which is underpinned
by rationale around clinical implications, is not applicable.
- Item 18
- Standard CONSORT item: results of any other
analyses performed, including subgroup analyses and
adjusted analyses, distinguishing prespecified from
exploratory
- Extension for pilot trials: results of any other analyses
performed that could be used to inform the future de-
finitive RCT
- Example
“Sensitivity analysis
At both six and 12 weeks, findings were insensitive to
the exclusion of those catheterised throughout their
hospital stay (and also to the exclusion of those who
were never incontinent following the removal of a
catheter). However, at both time points, odds ratios
reduced when those with pre-stroke incontinence
were excluded…” [79]
- Explanation
It is possible that the results of analyses that were not
initially planned might have important implications for
the future definitive RCT. Such findings should be re-
ported and discussed in relation to how they might in-
form the future definitive RCT. In the example, although
numbers were small, the authors inferred from the un-
planned sensitivity analyses that those with pre-stroke
incontinence were at least as likely, or more likely, to
benefit from the intervention than those continent pre-
stroke, and concluded that this group of patients should
be included in the full trial.
- Item 19
- Standard CONSORT item: all important harms or
unintended effects in each group (for specific guidance
see CONSORT for harms) [7]
- Example 1 (potential harm)
“Intervention and usual treatment groups were similar
in terms of age, gender, and marital status, but those
in the intervention group were more likely to be
unemployed (69 v. 59 %), to use methods other than
poisoning (23 v. 9 %), to have a past history of self-harm
(67 v. 53 %) and to have had previous psychiatric
treatment (64 v. 53 %).
Online Table DS1 shows self-harm repetition and
resource use in the two groups. The 12-month repeat
rate for individuals in the intervention group was 34.4
v. 12.5 % for the usual treatment group (odds ratio
(OR) 3.67, 95 % CI 1.0–13.1 …)…Adjusting for baseline
clinical factors (centre, method of harm (self-poisoning
v. other), previous self-harm, previous psychiatric
treatment), the odds ratio for repetition and incidence
rate ratio for number of repeat episodes remained
elevated…” [80]
- Example 2 (unintended effect or potential harm)
“An unanticipated finding in this study was a 4-kg
weight loss, on average, favouring the intervention
group, although we recognized that there were some
differences in weight between groups at study
commencement that may have had an effect on our
results…Thus, there is a clear role for dietary
considerations in any study that aims to positively
influence body weight. Although we provided one
educational session on nutrition during a tour of a
local grocery store with a dietitian and modelled
healthy food choices with the lunches provided,
dietary behaviors and body weight were not the
focus of the study [21].”
- Explanation
It is crucial to report all important or potential harms
or unintended effects on individual participants in each
group to enable the study design for the future definitive
RCT to be changed either to avoid these effects or to
put in place effective processes for monitoring potential
harms. In example 1, it was not clear whether the unex-
pected increased risk of repeated self harm in the inter-
vention group was real or a consequence of baseline
covariate imbalance, or peculiar to the particular setting.
This led to a proposal to change the design to use strati-
fied randomisation in the future definitive RCT. In ex-
ample 2, the unintended effect of weight loss in elderly
participants led to the decision to include a dietary com-
ponent in the intervention to avoid potential harm in the
future definitive RCT. This information might also be use-
ful to other researchers planning similar studies.
- Item 19a
- Extension for pilot trials: if relevant, other important
unintended consequences
- Example (unintended consequence)
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“Twelve of the 13 active, and 11 of the 13 traditional
practices recruited a total of 231 participants in the
12 months from mid-April 1998. Active practices
recruited 165 (average practice recruitment rate of
1.71 per 1000 registered patients, i.e., 141 % of expected)
while traditional practices recruited only 66 (0.57 per
1000 i.e. 54 % of expected) (Fig. 1). On average active
practices recruited 12.7 participants (range 0–39), while
traditional practices recruited only 5.1 participants
(range 0–18) (Table 2). Although both types of practices
recruited similar percentages of those identified (13 % in
active; 16 % in traditional), active identified 1257, far
more than the 416 by traditional practices. The extreme
difference in recruitment rates led to an investigation of
baseline characteristics of participants in the two groups
(Table 3). Participants recruited by active practices were
more likely to be working full-time and to have had
further education since leaving school. They were also
suffering from milder back pain, less limited physically
and less depressed [81].”
- Explanation
This is a new item reflecting the importance of report-
ing unintended consequences that do not directly affect
individual participants but might have implications for
the validity of the future definitive RCT if not dealt with
in the pilot trial. By unintended consequences we mean
things that happened in the pilot trial that the investiga-
tors did not intend to look for but that would have such
implications. In the example, the design of the pilot
trial included practice level randomisation, with partici-
pant recruitment after that randomisation. This had
unintended consequences in the balance of recruited
participants between arms, and in the main study the
researchers abandoned randomisation at the practice
level.
Discussion
- Item 20
- Standard CONSORT item: trial limitations, address-
ing sources of potential bias, imprecision, and, if rele-
vant, multiplicity of analyses
- Extension for pilot trials: pilot trial limitations, ad-
dressing sources of potential bias and remaining uncer-
tainty about feasibility
- Example 1 (pilot trial limitations)
“In some cases, platelet mass was calculated on an
MPV [mean platelet volume] that was up to 72 hours
old based on our previous research on the
relationship between platelet mass and IVH
[intraventricular hemorrhage]. We cannot rule out the
possibility that during acute thrombocytopenia
changes in MPV may be more acute. Because platelet
counts were not confirmed by manual count, we
cannot exclude the unlikely possibility that some
infants may have had pseudothrombocytopenia [82].”
- Example 2 (potential bias)
“Fourth, the house staff at the two academic centers
in the study may have been a source of contamination.
Additional house staff occasionally provided overnight
coverage at the intervention group academic center.
These additional house staff were not formally educated
about the study, so they effectively functioned as if they
were in the control group. Conversely, additional
house staff who provided overnight coverage at the
control group academic center may have been
previously educated about our study while working
at the intervention group academic center. Thus,
they effectively functioned as if they were in the
intervention group [83].”
- Example 3 (remaining uncertainty)
“The integration of a nested, internal pilot in the
definitive trial should also be considered to allow
continued monitoring of the feasibility, in particular,
the assessment of using different inclusion criteria
and the recommended changes to the data collection
methods, particularly within the first year of recruitment.
The use of a qualitative element to assess the participants’
views on data collection methods would also be
beneficial [84].”
- Explanation
Identifying and discussing the limitations of a study
helps to provide a better context for understanding the
importance of its findings. In a pilot trial it might also
be helpful to distinguish between limitations that can be
overcome in a future definitive RCT, and those that can-
not. In example 1 the authors explain the limitation of a
method of measurement although they do not say whether
they think this could be overcome in a future definitive
RCT.
In a future definitive RCT, investigators will want, as
far as possible, to avoid sources of bias that might affect
treatment effect estimates. In a pilot trial, investigators
are not primarily interested in treatment effect, so these
biases will not be of so much concern but it would still
be useful to identify potential biases that could affect the
treatment effect in the future definitive RCT so that in-
vestigators have a better chance of avoiding these. In ex-
ample 2 a potential source of bias in the future definitive
RCT is identified.
If substantial areas of uncertainty about feasibility re-
main at the end of the pilot trial that prevent
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investigators from proceeding with a future definitive
RCT or warrant investigation in an internal pilot then,
for clarity, these should be reported, as in example 3.
Lastly, although we do not recommend this, if under-
powered tests are performed and reported then investi-
gators should always point out this limitation to avoid
misinterpretation of results (see item 2b).
- Item 21
- Standard CONSORT item: generalisability (external
validity, applicability) of the trial findings
- Extension for pilot trials: generalisability (applicability)
of pilot trial methods and findings to future definitive trial
and other studies
- Example 1 (generalisability of findings)
“We accommodated variability in choice and duration
of standard treatments to enhance generalizability of
the results and had high rates of follow-up.” [65]
- Example 2 (generalisability to other pilot trials)
“Our data reflect the activities of only one pilot trial;
however, we hope that the methods may serve as a
template for analyzing other pilot studies with
different designs in other settings [63].”
- Example 3 (generalisability concerns)
“Although safety issues must remain paramount in
practice and clinical research, common overstringent
exclusion criteria may increase perceived trial safety
yet limit the generalizability of trial results and delay
answers to important clinical questions. Reevaluation
of the PROTECT Pilot exclusion criteria will…
enhance the applicability of the larger PROTECT
study…The PROTECT Pilot indicated the need for
another pilot study (DIRECT) to determine the safety
of dalteparin 5000 IU SC OD among patients with
severe renal insufficiency (creatinine clearance, b30
mL/min) [63].”
- Explanation
Generalisability (applicability) is the extent to which
aspects of a study can be applied to other circumstances.
Generalisability is not absolute and is a matter of judg-
ment. In a definitive trial, readers are usually interested
in the generalisability of findings to situations outside re-
search settings—for example, routine clinical practice.
However, in pilot trials this is not the case because the
size of these studies does not allow this. Nevertheless, it
might be important to consider generalisability at the
pilot stage as this could be important for the generalis-
ability of the future definitive RCT (example 1), the find-
ings and the methods might be applied in research
settings other than the future definitive RCT (example
2), or there might be concerns about the generalisability
of results from a future definitive RCT conducted in an
identical way to the pilot trial that might lead to changes
in the design of the future definitive RCT or further
piloting (example 3).
- Item 22
- Standard CONSORT item: interpretation consistent
with results, balancing benefits and harms, and consider-
ing other relevant evidence
- Extension for pilot trials: interpretation consistent
with pilot trial objectives and findings, balancing poten-
tial benefits and harms, and considering other relevant
evidence
- Example 1 (consistency with objectives and findings)
“One of the goals of this pilot study was to investigate
the feasibility of using platelet transfusion guidelines
based on platelet mass. In five infants, MPV [mean
platelet volume] was not available within 72 hours
preceding the diagnosis of thrombocytopenia. A lack
of immediately available MPV may limit the clinical
utility and generalizability of this transfusion strategy
at some institutions…In our study approximately half
of the families at the Christiana Hospital site did not
consent to the study. This information is important
for planning future studies on platelet transfusion.
Many families were unable to decide on enrollment at
a time when their infant was thrombocytopenic and
facing transfusion. An alternative study design for
platelet transfusion study may involve enrolling a
larger number of infants on admission, regardless of
platelet count, with transfusion guidelines to apply
only if they actually become thrombocytopenic. This
approach may limit the stress on families of being
approached about the need for transfusion and a
transfusion related study simultaneously [82].”
- Example 2 (considering other relevant evidence)
“As far as we know, our participants were able to
perform motor imagery. Our results seem to be in
contrast to previous studies demonstrating a lower
capacity for motor imagery in people with MS.
However, these authors linked impaired motor
imagery in this population particularly to cognitive
dysfunction and depression. Therefore, persons with
cognitive impairment and depression were excluded
from our study. Several studies used patient-rated
questionnaires, such as the Kinaesthetic and Visual
Imagery Questionnaire to assess the motor imagery
ability in their participants. Our study could have used
this patient-rated questionnaire, but our participants
were called weekly to ask for any problems with
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kinaesthetic motor imagery, and they were supported
accordingly. In addition, all motor imagery ability
studies in people with MS were experimental studies
with no long-term training effects, in contrast to our
4 weeks duration study with 24 training sessions which
might have enhanced the mental representation [68].”
- Example 3 (consistency with findings in relation to
decision criteria)
“Moreover, the results of this trial support the
feasibility and acceptability of conducting a large
clustered randomised trial involving dyads of family
physicians and their patients in SDM regarding the
optimal use of antibiotics for ARI. This conclusion is
reached even if not all predetermined standards for
our criteria were always fully met. Indeed, it has been
established that not reaching the preestablished
criteria does not necessarily indicate unfeasibility of
the trial but rather underlines changes to be made to
the protocol…24 % of the eligible FMGs agreed to
take part in the study, less than the 50 % expected. We
were probably too confident when targeting a 50 %
positive response rate from all identified FMGs [34].”
- Explanation
Interpretation of findings helps increase understanding
of the importance of the results. In example 1, in
addition to matching their interpretation to one of the
goals of the study, the authors draw out the issue of re-
design to reduce stress in families approached and so in-
crease recruitment—and hopefully eventually a positive
benefit for the children involved. This observation could
be helpful to others planning similar studies. As for de-
finitive trials, readers will want to know how the evi-
dence presented in the report of a pilot trial relates to
evidence from other sources (example 2). These sources
might be other feasibility studies carried out by the au-
thors or studies by different authors in the same or similar
settings or with similar patients. If a priori decision criteria
have been used (item 6c) then interpretation should be
made with reference to these criteria (example 3).
- Item 22a
- Extension for pilot trials: implications for progression
from pilot to future definitive trial, including any proposed
amendments
- Example 1 (proposed amendments to improve
recruitment)
“The target of recruit to time was met but this did
not translate to the expected number of eligible
patients being recruited. Eligibility of the screened
population was much lower than expected,
indicating that the inclusion criteria may have been
too stringent. The exclusion criteria of BMI ≤22 kg/
m2 was based on published evidence that a BMI at
the lower end of the normal range can increase
mortality in the haemodialysis population…
However, body composition is thought to play a
much greater role in the protective effects of a
greater BMI, than the BMI itself…The use of BMI as
a screening tool was a quick and easy measure but
the level of ≤22 kg/m2 should be reassessed prior to
a definitive trial. If the BMI was raised to ≤24 kg/m2
then this would have increased potential
recruitment by 10 % [84].”
- Example 2 (proposed amendments to improve
cooperation)
“Six homes declined to actively participate before
even beginning the intervention. To ensure
cooperation by the entire team and avoid early
withdrawal, a short presentation to the Professional
Advisory Committee team could potentially boost
recruitment/retention. Obtaining initial consent from
both the medical director and director of care may
also be beneficial. Furthermore, to overcome
logistical challenges, particularly for homes in the far
north, providing an opportunity to view modules on a
Web site or participate remotely may improve
participation [85].”
- Example 3 (implications for progression to future de-
finitive RCT)
“Hospitals that were allocated to receive our
multicomponent intervention comprising
education, standardized paper-based physician
orders, and group audit and feedback did not have a
higher rate of hospitalized medical patients appro-
priately managed for thromboprophylaxis within
24 hours of admission than did hospitals that were
not allocated to this strategy (63 % vs. 67 %). This
finding, coupled with the problems associated with
ensuring preprinted orders were placed in all med-
ical charts led us to conclude that this intervention
should not be provided on a larger scale without
major revision and testing. That is, it was not
feasible [83].”
- Explanation
This is a new item. To progress from a pilot trial to a
future definitive RCT, it is important to understand how
the implications of the findings in the pilot carry over
to the future definitive RCT. To aid clarity, a simple
statement as to whether the future definitive RCT will
be planned without any changes from the pilot trial,
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planned with changes from the pilot trial (examples 1
and 2), or not planned because of major problems with
feasibility (example 3), is sufficient. If it is proposed to
plan the future definitive RCT with specific changes
from the pilot trial, these should be stated.
Other information
- Item 23
- Standard CONSORT item: registration number and
name of trial registry
- Extension for pilot trials: registration number for
pilot trial and name of trial registry
- Example
“Trial registration number: Clinical Trials, protocol
registration system: NCT01695070 [86].”
- Explanation
It is just as important for a pilot trial to be registered
with a unique identifier as it is for a definitive trial. Regis-
tration ensures transparency and accountability and in the
United Kingdom is now a requirement for all clinical trials
before approval from UK ethics committees [87, 88] It en-
sures all ongoing work is in the public domain, and subse-
quent publication (and therefore access to findings for the
greater good) confirmed. The World Health Organization
states that “the registration of all interventional trials is a
scientific, ethical and moral responsibility [89].” The Inter-
national Committee of Medical Journal Editors requires
all trials to be registered as a criterion for publication and
lists suggested registries [90].
- Item 24
- Standard CONSORT item: where the full trial proto-
col can be accessed, if available
- Extension for pilot trials: where the pilot trial proto-
col can be accessed, if available
- Example 1 (reference to published protocol)
“The Healthy Hospital Trial is a single-center,
randomized controlled, 2-arm, parallel-group, unblinded
feasibility trial that was conducted on 2 cardiology wards
at the Leeds Teaching Hospitals Trust. Its primary aim
was to explore the feasibility of individualized lifestyle
referral assessment, estimate the rate of recruitment,
and explore the feasibility of collecting the data and
follow-up of participants to inform the sample size of a
definitive trial....The trial protocol has been published
elsewhere [40].”
- Example 2 (protocol as supporting information)
“The protocol for this trial and supporting TREND
checklist are available as supporting information; see
Checklist S1 and Protocol S1 [91].”
- Example 3 (protocol available from authors on
request)
“Participants in the control arm (but not the other
two arms) received a 16-page informational booklet
relevant to education, medical care, housing, employ-
ment, and community resources (protocol available from
authors upon request) [92].”
- Explanation
Access to the full protocol for the pilot trial is important
as it will prespecify all the main components of the trial.
The SPIRIT (standard protocol items: recommendations
for interventional trials) statement defines an evidence
based set of items that would be included [93]. Accessibility
of the protocol allows subsequent output to be checked for
completeness, and reduces the chance of selective reporting
to suggest “better” results. The examples illustrate the dif-
ferent ways in which protocols may be made available, such
as prior publication (example 1), as an addendum to the re-
port of the pilot trial (example 2), or on request from the
authors (example 3). Options where the protocol is already
in the public domain, such as prior publication, are to be
preferred. Other methods that could be used to achieve this
would include publication on a study website. Trial regis-
tries (see item 23) also include some core protocol items.
- Item 25
- Standard CONSORT item: sources of funding and
other support (such as supply of drugs), role of funders
- Example
“Funding: This trial was funded through grants from
Academic Health Science Centres Alternative Funding
Plan Innovation Fund of Ontario and Octapharma
Canada. The trial funders had no role in the design of
the study, the collection, analysis or interpretation of
data, the writing of the report, or the decision to
submit the article for publication [94].”
- Explanation
Reporting the sources of all funding for a pilot trial
(that is, the main research award and any other sup-
port, such as supply of equipment) allows readers to
judge the potential influence of the funding body on
the design, conduct, analysis, and reporting of the trial.
If no specific funding was provided to support the pilot
trial, this should also be stated. As reported in the main
CONSORT statement, a systematic review has shown
that research funded by the pharmaceutical industry is
more likely to report findings in its favour, compared
with reports of research funded by independent funding
bodies [2, 61] Where funders have had no involvement
in any aspect of trial conduct or reporting this should
be explicitly stated.
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- Item 26
- Extension for pilot trials: ethical approval/research
review committee approval confirmed with reference
number
- Example
“The Regional Ethical Review Board at the Karolinska
Institute approved the study, no. 2007/1401-31/3 [95].”
- Explanation
This is a new item that has been added to the CON-
SORT checklist because of the need to emphasise that
all research, including pilot trials, should only be con-
ducted within an ethical framework and with all ethical
and other approvals in place before commencement. Of
particular relevance to pilot trials is the need also to be
aware of any restrictions imposed by the reviewing eth-
ical committee, because these would have implications
for the design and conduct of the future definitive RCT.
Comment
Reports of RCTs need to include key information on the
methods and results so that readers can accurately inter-
pret the contents of the report. This is as true for pilot
trials as it is for any other RCT. The CONSORT 2010
statement provides the latest recommendations from the
CONSORT Group on essential items to be included in
the report of an RCT [2, 61] However, pilot trials differ
from other randomised trials in their aims and objec-
tives, focusing on assessing feasibility rather than effect-
iveness or efficacy. Therefore, although much of the
information to be reported in these trials is similar to
that which needs to be reported in any other randomised
trial, there are some key differences in the type of infor-
mation and in the appropriate interpretation of standard
CONSORT reporting items.
In this article we introduce and explain these key dif-
ferences in an extension to the CONSORT checklist spe-
cific to pilot trials. In the section entitled “Scope of this
paper” we discuss several other types of feasibility study,
and “proof of concept” trials. Other researchers have
begun to look at the transfer of ideas between these differ-
ent types of study (eg, Wilson et al [96]). It is our expect-
ation that some of the principles of reporting outlined in
this extension can be adapted for other types of feasibility
or proof of concept studies.
Use of the CONSORT statement for the reporting of two
group parallel trials is associated with improved reporting
quality [97]. We believe that the routine use of this pro-
posed extension to the CONSORT statement will result in
similar improvements in reporting of pilot trials. When
reporting a pilot trial, authors should address each of the
26 items on the CONSORT extension checklist using this
document, referring to the main CONSORT guidelines as
appropriate. Adherence to the CONSORT statement and
extensions can also help researchers designing trials in the
future and can guide peer reviewers and editors in their
evaluation of manuscripts. Many journals recommend ad-
herence to the CONSORT recommendations in their in-
structions to authors. We encourage them to direct authors
to this and to other extensions of CONSORT for specific
trial designs. A tool is currently being developed to support
journals in doing this [98]. The most up to date versions of
all CONSORT recommendations are available at www.con-
sort-statement.org.
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